Trial record 2 of 756 for:
Fibrinolytic Therapy | Recruiting, Not yet recruiting, Active, not recruiting, Completed, Enrolling by invitation Studies | Industry
Fibrinolytic Deficit in Patients With Acute PE
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04480892 |
Recruitment Status :
Not yet recruiting
First Posted : July 22, 2020
Last Update Posted : July 22, 2020
|
Sponsor:
Loyola University
Collaborator:
Boston Scientific Corporation
Information provided by (Responsible Party):
Amir Darki, Loyola University
Tracking Information | |||||
---|---|---|---|---|---|
First Submitted Date | June 28, 2020 | ||||
First Posted Date | July 22, 2020 | ||||
Last Update Posted Date | July 22, 2020 | ||||
Estimated Study Start Date | August 2020 | ||||
Estimated Primary Completion Date | December 2023 (Final data collection date for primary outcome measure) | ||||
Current Primary Outcome Measures |
|
||||
Original Primary Outcome Measures | Same as current | ||||
Change History | No Changes Posted | ||||
Current Secondary Outcome Measures | Not Provided | ||||
Original Secondary Outcome Measures | Not Provided | ||||
Current Other Pre-specified Outcome Measures | Not Provided | ||||
Original Other Pre-specified Outcome Measures | Not Provided | ||||
Descriptive Information | |||||
Brief Title | Fibrinolytic Deficit in Patients With Acute PE | ||||
Official Title | Fibrinolytic Deficit in Patients With Acute Pulmonary Embolism | ||||
Brief Summary | Fibrinolysis is the body's process that prevents blood clots. The investigators hypothesize that patients presenting with acute pulmonary embolism (PE) or blood clots in the lungs differ in their fibrinolytic deficit phenotype. The investigators aim to use biomarkers directly involved in endogenous fibrinolytic cascade including PAI-1, Alpha-2-Antiplasmin (A2A), TAFI, D-dimer, and Fibrinogen to phenotypically characterize patients presenting with acute PE and to correlate these biomarkers with clinical, echocardiographic, computed tomography (CT), and functional status outcomes. | ||||
Detailed Description | Patients (n=100) identified by the Pulmonary Embolism Response Team (PERT) suffering from a PE will be identified by the PI. Blood plasma samples from these patients which have been drawn for routine lab tests will be identified and the Sub-I who will pick the samples up from the clinical lab after the routine analysis has been completed. These samples will be de-identified by giving them a study number. These samples will be recentrifuged and aliquoted. Samples will be stored in a -80ᵒC freezer in the Hemostasis & Thrombosis Research Laboratory. When all 100 de-identified samples have been collected they will be analyzed blindly by the technical staff of the hemostasis laboratory for the fibrinolytic parameters PAI-1, Alpha-2-Antiplasmin, TAFI, tPA, D-dimer, Plasminogen, and Fibrinogen. PAI-1 and TAFI will be quantified with an Enzyme Linked-Immuno-Sorbent Assay (ELISA), while A2A is measured using functional assay. PAI-1 is measured as ug/ml, while TAFI and A2A are measured as % of normal controls. Normal controls are derived from pooled normal human plasma from volunteers purchased from outside vendor. Results will be compiled and sent to the PERT team for analysis and correlation withclinical, echocardiographic, computed tomography (CT), and functional status outcomes. | ||||
Study Type | Observational [Patient Registry] | ||||
Study Design | Observational Model: Cohort Time Perspective: Prospective |
||||
Target Follow-Up Duration | 1 Day | ||||
Biospecimen | Retention: Samples With DNA Description: Blood samples drawn for clinical evaluation of PE will be collected after analysis complete, de-identified, re-centrifuged, aliquoted, and stored in -80 freezer. Once all 100 patient samples have been collected, samples will be analyzed for fibrinolytic biomarkers.
|
||||
Sampling Method | Non-Probability Sample | ||||
Study Population | Patients with acute PE being treated by the PERT. | ||||
Condition |
|
||||
Intervention | Not Provided | ||||
Study Groups/Cohorts | Not Provided | ||||
Publications * |
|
||||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|||||
Recruitment Information | |||||
Recruitment Status | Not yet recruiting | ||||
Estimated Enrollment |
100 | ||||
Original Estimated Enrollment | Same as current | ||||
Estimated Study Completion Date | December 2024 | ||||
Estimated Primary Completion Date | December 2023 (Final data collection date for primary outcome measure) | ||||
Eligibility Criteria | Inclusion Criteria:
Exclusion Criteria:
|
||||
Sex/Gender |
|
||||
Ages | 18 Years to 90 Years (Adult, Older Adult) | ||||
Accepts Healthy Volunteers | No | ||||
Contacts |
|
||||
Listed Location Countries | United States | ||||
Removed Location Countries | |||||
Administrative Information | |||||
NCT Number | NCT04480892 | ||||
Other Study ID Numbers | 212490 | ||||
Has Data Monitoring Committee | No | ||||
U.S. FDA-regulated Product |
|
||||
IPD Sharing Statement |
|
||||
Current Responsible Party | Amir Darki, Loyola University | ||||
Original Responsible Party | Same as current | ||||
Current Study Sponsor | Loyola University | ||||
Original Study Sponsor | Same as current | ||||
Collaborators | Boston Scientific Corporation | ||||
Investigators |
|
||||
PRS Account | Loyola University | ||||
Verification Date | July 2020 |